<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Nutr Metab</journal-id><journal-id journal-id-type="iso-abbrev">J Nutr Metab</journal-id><journal-id journal-id-type="publisher-id">JNME</journal-id><journal-title-group><journal-title>Journal of Nutrition and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">2090-0724</issn><issn pub-type="epub">2090-0732</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29686895</article-id><article-id pub-id-type="pmc">5852865</article-id><article-id pub-id-type="doi">10.1155/2018/4632081</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of Diacetate Esters of Macular Carotenoids: Effect of Supplementation on Macular Pigment</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3723-3604</contrib-id><name><surname>Bone</surname><given-names>Richard A.</given-names></name><email>bone@fiu.edu</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Landrum</surname><given-names>John T.</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4910-9587</contrib-id><name><surname>Mukherjee</surname><given-names>Anirbaan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Physics, Florida International University, Miami, FL 33199, USA</aff><aff id="I2">
<sup>2</sup>Department of Chemistry and Biochemistry, Florida International University, Miami, FL 33199, USA</aff><author-notes><fn fn-type="other"><p>Academic Editor: C. S. Johnston</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>1</day><month>3</month><year>2018</year></pub-date><volume>2018</volume><elocation-id>4632081</elocation-id><history><date date-type="received"><day>27</day><month>7</month><year>2017</year></date><date date-type="rev-recd"><day>20</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>18</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>Copyright © 2018 Richard A. Bone et al.</copyright-statement><copyright-year>2018</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><offsets xml_i="3108" xml_f="3235" txt_i="11" txt_f="138">The accumulation of the carotenoids lutein, zeaxanthin, and mesozeaxanthin in the center of the human retina, and known as the </offsets><italic><offsets xml_i="3243" xml_f="3255" txt_i="138" txt_f="150">macula lutea</offsets></italic><offsets xml_i="3264" xml_f="4009" txt_i="150" txt_f="895"> or macular pigment, is believed to protect the retina from age-related macular degeneration. Since the macular pigment is of dietary origin, supplements containing the relevant carotenoids are readily available. In this study, we compared the changes in macular pigment over a 24-week supplementation period for two groups of 24 subjects each assigned to either of two supplement formulations, 20 mg/day of lutein or 20 mg equivalent free carotenoids of a combination of diacetate esters of the macular carotenoids. The latter group responded with a larger increase (0.0666 ± 0.0481) in macular pigment optical density than the former group (0.0398 ± 0.0430), driven largely by the older subjects. The difference was statistically significant (</offsets><italic><offsets xml_i="4017" xml_f="4018" txt_i="895" txt_f="896">p</offsets></italic><offsets xml_i="4027" xml_f="4199" txt_i="896" txt_f="1068">=0.0287). There was a general trend towards smaller increases in macular pigment for those subjects whose baseline value was high. However, the trend was only significant (</offsets><italic><offsets xml_i="4207" xml_f="4208" txt_i="1068" txt_f="1069">p</offsets></italic><offsets xml_i="4217" xml_f="4462" txt_i="1069" txt_f="1311"> &lt; 0.05) for subjects in the diacetate group. No differences in response could be attributed to the gender of the subjects. We also observed no indication that the use of statin drugs by a few of the older subjects influenced their responses.</offsets></p></abstract><funding-group><award-group><funding-source>Industrial Orgánica S.A. de C.V.</funding-source></award-group><award-group><funding-source>Beneseed Co., Ltd.</funding-source></award-group></funding-group></article-meta></front><body><sec id="sec1"><title><offsets xml_i="4729" xml_f="4744" txt_i="1319" txt_f="1334">1. Introduction</offsets></title><p><offsets xml_i="4755" xml_f="4946" txt_i="1335" txt_f="1526">The macular carotenoids, or xanthophylls, lutein (L), zeaxanthin (Z), and mesozeaxanthin (MZ) are found throughout the human retina but are particularly concentrated in and around the fovea [</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="4977" xml_f="4978" txt_i="1526" txt_f="1527">1</offsets></xref><offsets xml_i="4985" xml_f="5143" txt_i="1527" txt_f="1685">]. As both antioxidants and blue light blockers, they are believed to protect against degenerative retinal diseases such as age-related macular degeneration [</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="5174" xml_f="5175" txt_i="1685" txt_f="1686">2</offsets></xref><offsets xml_i="5182" xml_f="5229" txt_i="1686" txt_f="1733">] and also, potentially, diabetic retinopathy [</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="5260" xml_f="5261" txt_i="1733" txt_f="1734">3</offsets></xref><offsets xml_i="5268" xml_f="5311" txt_i="1734" txt_f="1777">] and retinitis pigmentosa/Usher syndrome [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="5342" xml_f="5343" txt_i="1777" txt_f="1778">4</offsets></xref><offsets xml_i="5350" xml_f="5483" txt_i="1778" txt_f="1911">]. Because the density of macular pigment in the retina responds positively to dietary supplementation with the macular carotenoids [</offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="5514" xml_f="5515" txt_i="1911" txt_f="1912">5</offsets></xref><offsets xml_i="5522" xml_f="5718" txt_i="1912" txt_f="2108">], it is appropriate to study different formulations with regard to their efficacy of absorption into the retinal tissues. The major source of L for the supplement industry is the marigold bloom (</offsets><italic><offsets xml_i="5726" xml_f="5740" txt_i="2108" txt_f="2122">Tagetes erecta</offsets></italic><offsets xml_i="5749" xml_f="5865" txt_i="2122" txt_f="2238">) where L is found in esterified form (56% lutein dipalmitate, 36% lutein dimyristate, and 8% lutein monomyristate [</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="5896" xml_f="5897" txt_i="2238" txt_f="2239">6</offsets></xref><offsets xml_i="5904" xml_f="6060" txt_i="2239" txt_f="2395">]). However, the extraction and purification process, which typically involves alkaline saponification, results in free L. In order to obtain L esters from </offsets><italic><offsets xml_i="6068" xml_f="6077" txt_i="2395" txt_f="2404">T. erecta</offsets></italic><offsets xml_i="6086" xml_f="6122" txt_i="2404" txt_f="2440">, a food-grade solvent is employed [</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="6153" xml_f="6154" txt_i="2440" txt_f="2441">7</offsets></xref><offsets xml_i="6161" xml_f="6424" txt_i="2441" txt_f="2704">]. Both free and esterified L are commercially available in the supplement form. A comparative study found that the bioavailability of the esterified form was higher than that for the free form as indicated by the increased uptake into the blood serum of free L [</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="6455" xml_f="6456" txt_i="2704" txt_f="2705">6</offsets></xref><offsets xml_i="6463" xml_f="6825" txt_i="2705" txt_f="3067">]. (Following ingestion, the L esters are hydrolyzed prior to reaching the circulation.) The suggested reason for the higher bioavailability was the better dispersion, solubilization, and incorporation of L esters into micelles formed in the digestive process, compared with free L. However, this study contradicts a more recent crossover study by Chung et al. [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="6856" xml_f="6857" txt_i="3067" txt_f="3068">8</offsets></xref><offsets xml_i="6864" xml_f="6994" txt_i="3068" txt_f="3198">] in which no significant differences in serum response were observed when the subjects were taking free L or L ester supplements.</offsets></p><p><offsets xml_i="7001" xml_f="7623" txt_i="3199" txt_f="3821">L esters can also be synthesized from free L, and the same is true for the other macular carotenoids, Z and MZ. The purpose of the present study was to determine the efficiency of absorption of a mixture of diacetate esters of L, Z, and MZ (Micro Mic™), relative to free L. Free L appears to be the most common commercially available supplement aimed at improving the health of the eye and was therefore considered an appropriate control for this study. Since the ultimate target tissue for the carotenoids is the retina, the efficiency of absorption was determined by directly measuring retinal levels of macular pigment.</offsets></p></sec><sec id="sec2"><title><offsets xml_i="7655" xml_f="7679" txt_i="3823" txt_f="3847">2. Materials and Methods</offsets></title><sec id="sec2.1"><title><offsets xml_i="7711" xml_f="7730" txt_i="3848" txt_f="3867">2.1. Study Duration</offsets></title><p><offsets xml_i="7741" xml_f="7872" txt_i="3868" txt_f="3999">Blood serum levels of carotenoids generally respond rapidly to carotenoid supplementation, reaching a plateau after about 4 weeks [</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="7903" xml_f="7904" txt_i="3999" txt_f="4000">9</offsets></xref><offsets xml_i="7911" xml_f="8166" txt_i="4000" txt_f="4255">]. However, because the macular pigment responds more slowly, we adopted a 24-week supplementation period. Past studies have shown that during such a time period, significant changes in macular pigment optical density (MPOD) can generally be anticipated [</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="8197" xml_f="8198" txt_i="4255" txt_f="4256">9</offsets></xref><offsets xml_i="8205" xml_f="8207" txt_i="4256" txt_f="4258">, </offsets><xref rid="B10" ref-type="bibr"><offsets xml_i="8239" xml_f="8241" txt_i="4258" txt_f="4260">10</offsets></xref><offsets xml_i="8248" xml_f="8250" txt_i="4260" txt_f="4262">].</offsets></p></sec><sec id="sec2.2"><title><offsets xml_i="8284" xml_f="8309" txt_i="4264" txt_f="4289">2.2. Subject Demographics</offsets></title><p><offsets xml_i="8320" xml_f="9167" txt_i="4290" txt_f="5137">A total of 48 subjects were recruited from the students, faculty, and staff at Florida International University. Subjects signed an IRB-approved informed consent form, and the study complied with IRB regulations as well as the Declaration of Helsinki. In order to compare possible age effects on the response to supplementation, we recruited subjects in two age ranges, 18 to 30, and over 50 years of age. The subjects were then split into two supplement groups: Group 1, consisting of 24 subjects, received 20 mg per day of Micro Mic in a L : MZ : Z ratio of 10 : 10 : 2; Group 2, also consisting of 24 subjects, received 20 mg per day of L (note that commercially available L contains approximately 5% of Z). With 24 subjects in each group and a desired power of 0.80, a significant difference between groups of 0.03 in the change of MPOD, with </offsets><italic><offsets xml_i="9175" xml_f="9176" txt_i="5137" txt_f="5138">σ</offsets></italic><offsets xml_i="9185" xml_f="9255" txt_i="5138" txt_f="5208"> = 0.035, would be realizable. Subject demographics are summarized in </offsets><xref ref-type="table" rid="tab1"><offsets xml_i="9289" xml_f="9296" txt_i="5208" txt_f="5215">Table 1</offsets></xref><offsets xml_i="9303" xml_f="9560" txt_i="5215" txt_f="5472">. The study was a single-blinded study with the subjects not being informed which supplement they were receiving. Subjects were not asked to modify their diets, and an assessment of their normal dietary intake of xanthophylls was not included in this study.</offsets></p></sec><sec id="sec2.3"><title><offsets xml_i="9594" xml_f="9610" txt_i="5474" txt_f="5490">2.3. Supplements</offsets></title><p><offsets xml_i="9621" xml_f="9841" txt_i="5491" txt_f="5711">The supplements were provided in the form of identical looking gel caps that subjects were instructed to take with a meal, one per day, throughout the supplementation period. Each gel cap contained 20 mg of carotenoids (</offsets><xref ref-type="table" rid="tab1"><offsets xml_i="9875" xml_f="9882" txt_i="5711" txt_f="5718">Table 1</offsets></xref><offsets xml_i="9889" xml_f="10498" txt_i="5718" txt_f="6327">) in vegetable oil. In the case of the diacetate esters, 20 mg refers to the amount of free carotenoids, that is, not including the masses of the diacetate groups. For the lutein gel caps, 20 mg refers to the total amount of carotenoid, ∼95% of which was L and ∼5% was Z. Subjects were also given a 7-day pill organizer to aid in compliance and a schedule for future visits including dates for receiving refills. Compliance was determined by counting remaining gel caps at the end of the study and using this information to determine the number taken as a percentage of the number that should have been taken.</offsets></p></sec><sec id="sec2.4"><title><offsets xml_i="10532" xml_f="10554" txt_i="6329" txt_f="6351">2.4. MPOD Measurements</offsets></title><p><offsets xml_i="10565" xml_f="10737" txt_i="6352" txt_f="6524">MPOD was determined at baseline (week 0), at weeks 6, 12, and 18 and at the conclusion (week 24) of the supplementation period. The instrument employed was the mapcat SF™ [</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="10769" xml_f="10771" txt_i="6524" txt_f="6526">11</offsets></xref><offsets xml_i="10778" xml_f="10947" txt_i="6526" txt_f="6695">], a heterochromatic flicker photometer that was used in a customized mode (cHFP). (“Customized” refers to using optimum flicker frequencies for the individual subject.)</offsets></p><p><offsets xml_i="10954" xml_f="12983" txt_i="6696" txt_f="8725">MPOD was obtained in the right eye of each subject except for those whose vision was markedly better in the left eye. The subject viewed a small, circular stimulus, 1.5° in diameter and provided with crosshairs that alternated between blue and green lights provided by LEDs. The blue light is strongly absorbed by the macular pigment while the green light is only weakly absorbed. The result, generally, is a flickering appearance of the stimulus due to mismatched luminances. In order to determine the customized flicker frequency, the subject first viewed the stimulus with the green light switched off. Starting with a high blue light frequency (∼45 Hz), the subject gradually reduced the frequency until flicker was just perceived (critical fusion frequency, CFF). For the next stage of the test, the frequency was set to 2/3 of the CFF. With both the blue and green LEDs turned on, the subject altered the intensity of the blue light until, at equiluminance, flicker stopped or was minimized. Small adjustments to the frequency were made if the subject reported either a range of no flicker (frequency too high) or inability to eliminate flicker (frequency to low). The subject's blue light intensity setting at equiluminance reflected the amount of attenuation of the blue light, principally by the macular pigment and also, and increasingly with age, by the lens. The whole procedure was repeated with a larger, 15° stimulus with crosshairs for central fixation, and a default frequency set at 5/6 of the CFF. For this phase of the test, the subjects were asked to adjust the blue luminance to eliminate flicker around the periphery of the stimulus while ignoring the residual flicker at the center. Subjects made five repeat measurements for each part of the test, and the test was deemed acceptable if the standard error in the mean MPOD was less than 0.015. The MPOD and standard error were calculated automatically by a programmed microprocessor in the mapcat SF. The calculations are described in Bone and Mukherjee [</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="13015" xml_f="13017" txt_i="8725" txt_f="8727">11</offsets></xref><offsets xml_i="13024" xml_f="13236" txt_i="8727" txt_f="8939">]. After a brief resting period, the entire test was repeated up to two more times. A weighted mean of the MPODs was calculated together with a standard error according to an algorithm published by Olive et al. [</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="13268" xml_f="13270" txt_i="8939" txt_f="8941">12</offsets></xref><offsets xml_i="13277" xml_f="13279" txt_i="8941" txt_f="8943">].</offsets></p></sec><sec id="sec2.5"><title><offsets xml_i="13313" xml_f="13338" txt_i="8945" txt_f="8970">2.5. Statistical Analysis</offsets></title><p><offsets xml_i="13349" xml_f="13493" txt_i="8971" txt_f="9115">Results are expressed as means ± SD. Increases in MPOD resulting from supplementation were tested for significance using an independent-samples </offsets><italic><offsets xml_i="13501" xml_f="13502" txt_i="9115" txt_f="9116">t</offsets></italic><offsets xml_i="13511" xml_f="13518" txt_i="9116" txt_f="9123">-test (</offsets><italic><offsets xml_i="13526" xml_f="13527" txt_i="9123" txt_f="9124">α</offsets></italic><offsets xml_i="13536" xml_f="13553" txt_i="9124" txt_f="9141"> = 2). Values of </offsets><italic><offsets xml_i="13561" xml_f="13562" txt_i="9141" txt_f="9142">p</offsets></italic><offsets xml_i="13571" xml_f="13717" txt_i="9142" txt_f="9285"> &lt; 0.05 were considered significant. Adjustments for potentially confounding factors such as body mass index were not included in the analyses.</offsets></p></sec></sec><sec id="sec3"><title><offsets xml_i="13755" xml_f="13765" txt_i="9288" txt_f="9298">3. Results</offsets></title><sec id="sec3.1"><title><offsets xml_i="13797" xml_f="13826" txt_i="9299" txt_f="9328">3.1. Retention and Compliance</offsets></title><p><offsets xml_i="13837" xml_f="14242" txt_i="9329" txt_f="9734">All but two of the subjects completed the study satisfactorily. Of these, one of the younger subjects from Group 1 had to return to her homeland for personal reasons, and one of the older subjects from Group 2 developed severe difficulties with performing the cHFP test. Thus, reliable data were obtained from 23 subjects in Group 1 (11 young and 12 old), and 23 subjects in Group 2 (12 young and 11 old).</offsets></p><p><offsets xml_i="14249" xml_f="14375" txt_i="9735" txt_f="9861">The average compliance, based on the percentage of pills taken, and associated standard deviation for each group are shown in </offsets><xref ref-type="table" rid="tab2"><offsets xml_i="14409" xml_f="14416" txt_i="9861" txt_f="9868">Table 2</offsets></xref><offsets xml_i="14423" xml_f="14424" txt_i="9868" txt_f="9869">.</offsets></p></sec><sec id="sec3.2"><title><offsets xml_i="14458" xml_f="14496" txt_i="9871" txt_f="9909">3.2. Effect of Supplementation on MPOD</offsets></title><p><offsets xml_i="14507" xml_f="15032" txt_i="9910" txt_f="10435">Positive changes in MPOD were obtained for the vast majority of the subjects. Eighteen subjects in Group 1 and fifteen subjects in Group 2 were considered as responders based on a change in MPOD greater than twice the standard error in the mean. Negative changes, usually very small, were observed for two subjects in Group 1, and four subjects in Group 2. In all but two of these cases, the presupplementation MPOD was high. The general effect of a high presupplementation MPOD on the change in MPOD will be discussed later.</offsets></p><p><offsets xml_i="15039" xml_f="15120" txt_i="10436" txt_f="10517">A robust response to supplementation is shown for one of the Group 1 subjects in </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="15152" xml_f="15160" txt_i="10517" txt_f="10525">Figure 1</offsets></xref><offsets xml_i="15167" xml_f="15516" txt_i="10525" txt_f="10874">. It indicates, via the linear regression line, a remarkably linear relationship that was in fact typical of the majority of subjects. Note that the regression line is weighted using the reciprocal of the variance at each data point as the weighting factor. The average changes in MPOD ± SD from week zero to week 24 are shown for the two groups in </offsets><xref ref-type="table" rid="tab3"><offsets xml_i="15550" xml_f="15557" txt_i="10874" txt_f="10881">Table 3</offsets></xref><offsets xml_i="15564" xml_f="15743" txt_i="10881" txt_f="11060">. Also shown are the changes expressed as percentages of the week zero value and the rate of change in MPOD, that is, the slope of the regression line. Using two-tailed Student's </offsets><italic><offsets xml_i="15751" xml_f="15752" txt_i="11060" txt_f="11061">t</offsets></italic><offsets xml_i="15761" xml_f="15856" txt_i="11061" txt_f="11156">-test, we found a significant difference when comparing the change in MPOD for the two groups (</offsets><italic><offsets xml_i="15864" xml_f="15865" txt_i="11156" txt_f="11157">p</offsets></italic><offsets xml_i="15874" xml_f="15883" txt_i="11157" txt_f="11166">=0.0287).</offsets></p></sec><sec id="sec3.3"><title><offsets xml_i="15917" xml_f="15973" txt_i="11168" txt_f="11224">3.3. Effect of Presupplementation MPOD on Change in MPOD</offsets></title><p><offsets xml_i="15984" xml_f="16121" txt_i="11225" txt_f="11362">There was a negative trend between the change in MPOD and the presupplementation MPOD for each group as well as for the combined groups. </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="16153" xml_f="16162" txt_i="11362" txt_f="11371"> Figure 2</offsets></xref><offsets xml_i="16169" xml_f="16619" txt_i="11371" txt_f="11821"> shows the results for Group 1, the only one exhibiting a significant correlation. The slope of the regression line (−0.154) indicates by extrapolation that, on average, we might expect no change in MPOD with supplementation for a subject whose presupplementation MPOD was ∼0.93. For Group 2, and for Groups 1 and 2 combined, the slope of the regression line, the degree of correlation, and the significance were as follows: Group 2 (slope = −0.041, </offsets><italic><offsets xml_i="16627" xml_f="16628" txt_i="11821" txt_f="11822">R</offsets></italic><sup><offsets xml_i="16642" xml_f="16643" txt_i="11822" txt_f="11823">2</offsets></sup><offsets xml_i="16649" xml_f="16659" txt_i="11823" txt_f="11833"> = 0.033, </offsets><italic><offsets xml_i="16667" xml_f="16668" txt_i="11833" txt_f="11834">p</offsets></italic><offsets xml_i="16677" xml_f="16726" txt_i="11834" txt_f="11883">=0.41); Groups 1 and 2 combined (slope = −0.070, </offsets><italic><offsets xml_i="16734" xml_f="16735" txt_i="11883" txt_f="11884">R</offsets></italic><sup><offsets xml_i="16749" xml_f="16750" txt_i="11884" txt_f="11885">2</offsets></sup><offsets xml_i="16756" xml_f="16766" txt_i="11885" txt_f="11895"> = 0.058, </offsets><italic><offsets xml_i="16774" xml_f="16775" txt_i="11895" txt_f="11896">p</offsets></italic><offsets xml_i="16784" xml_f="16792" txt_i="11896" txt_f="11904">=0.106).</offsets></p></sec><sec id="sec3.4"><title><offsets xml_i="16826" xml_f="16862" txt_i="11906" txt_f="11942">3.4. Effect of Age on Change in MPOD</offsets></title><p><offsets xml_i="16873" xml_f="17137" txt_i="11943" txt_f="12204">Since the subjects were recruited in either of two age groups (18–30 = “young,” &gt;50 = “old”), we were able to determine whether age was a significant factor in the MPOD response to supplementation. The MPOD response was quantified in three ways as indicated in </offsets><xref ref-type="table" rid="tab3"><offsets xml_i="17171" xml_f="17178" txt_i="12204" txt_f="12211">Table 3</offsets></xref><offsets xml_i="17185" xml_f="17312" txt_i="12211" txt_f="12338">: the overall change in MPOD, the percentage change in MPOD, and the rate of change in MPOD. The results ± SD are presented in </offsets><xref ref-type="table" rid="tab4"><offsets xml_i="17346" xml_f="17353" txt_i="12338" txt_f="12345">Table 4</offsets></xref><offsets xml_i="17360" xml_f="17471" txt_i="12345" txt_f="12456"> for the combined groups and for each individual group. Also included are the presupplementation MPODs and the </offsets><italic><offsets xml_i="17479" xml_f="17480" txt_i="12456" txt_f="12457">p</offsets></italic><offsets xml_i="17489" xml_f="17512" txt_i="12457" txt_f="12480"> values for two-tailed </offsets><italic><offsets xml_i="17520" xml_f="17521" txt_i="12480" txt_f="12481">t</offsets></italic><offsets xml_i="17530" xml_f="17573" txt_i="12481" txt_f="12524">-tests to test for significant differences.</offsets></p><p><offsets xml_i="17580" xml_f="17792" txt_i="12525" txt_f="12737">Since we found that the change in MPOD was significantly greater for Group 1 subjects when compared with Group 2 subjects, we made a similar comparison for the two age groups separately. The results are shown in </offsets><xref ref-type="table" rid="tab5"><offsets xml_i="17826" xml_f="17833" txt_i="12737" txt_f="12744">Table 5</offsets></xref><offsets xml_i="17840" xml_f="18041" txt_i="12744" txt_f="12945"> and indicate that the change in MPOD was greater for both old and young subjects in Group 1 compared with Group 2, but the difference in MPOD response was significant (∗) only for the older subjects (</offsets><italic><offsets xml_i="18049" xml_f="18050" txt_i="12945" txt_f="12946">p</offsets></italic><offsets xml_i="18059" xml_f="18067" txt_i="12946" txt_f="12954">=0.025).</offsets></p></sec><sec id="sec3.5"><title><offsets xml_i="18101" xml_f="18140" txt_i="12956" txt_f="12995">3.5. Effect of Gender on Change in MPOD</offsets></title><p><offsets xml_i="18151" xml_f="18423" txt_i="12996" txt_f="13268">Presupplementation MPOD was lower for the female subjects in the combined groups compared with the males but did not quite reach statistical significance. There were no differences between males and females for any measure of change in MPOD. The results are summarized in </offsets><xref ref-type="table" rid="tab6"><offsets xml_i="18457" xml_f="18464" txt_i="13268" txt_f="13275">Table 6</offsets></xref><offsets xml_i="18471" xml_f="18472" txt_i="13275" txt_f="13276">.</offsets></p></sec><sec id="sec3.6"><title><offsets xml_i="18506" xml_f="18549" txt_i="13278" txt_f="13321">3.6. Effect of Statin Use on Change in MPOD</offsets></title><p><offsets xml_i="18560" xml_f="18723" txt_i="13322" txt_f="13482">Statin use was restricted to the &gt;50 year old subjects, six in Group 1 and three in Group 2. The data for the nonusers and users of this drug are summarized in </offsets><xref ref-type="table" rid="tab7"><offsets xml_i="18757" xml_f="18764" txt_i="13482" txt_f="13489">Table 7</offsets></xref><offsets xml_i="18771" xml_f="18790" txt_i="13489" txt_f="13508">. Included are the </offsets><italic><offsets xml_i="18798" xml_f="18799" txt_i="13508" txt_f="13509">p</offsets></italic><offsets xml_i="18808" xml_f="18830" txt_i="13509" txt_f="13531"> values for Student's </offsets><italic><offsets xml_i="18838" xml_f="18839" txt_i="13531" txt_f="13532">t</offsets></italic><offsets xml_i="18848" xml_f="18882" txt_i="13532" txt_f="13566">-test for significant differences.</offsets></p></sec></sec><sec id="sec4"><title><offsets xml_i="18920" xml_f="18933" txt_i="13569" txt_f="13582">4. Discussion</offsets></title><p><offsets xml_i="18944" xml_f="19052" txt_i="13583" txt_f="13691">Retention of subjects was high with only 2 subjects out of 48 being unable to complete the study. Likewise, </offsets><xref ref-type="table" rid="tab2"><offsets xml_i="19086" xml_f="19093" txt_i="13691" txt_f="13698">Table 2</offsets></xref><offsets xml_i="19100" xml_f="19172" txt_i="13698" txt_f="13770"> shows a very high, and almost identical, compliance for the two groups.</offsets></p><p><offsets xml_i="19179" xml_f="19449" txt_i="13771" txt_f="14041">The results for Groups 1 and 2 revealed that the Micro Mic diacetate formulation assigned to Group 1 produced an average increase in MPOD that was 67% higher than that produced by the lutein formulation assigned to Group 2. The difference was statistically significant (</offsets><italic><offsets xml_i="19457" xml_f="19458" txt_i="14041" txt_f="14042">p</offsets></italic><offsets xml_i="19467" xml_f="19533" txt_i="14042" txt_f="14105"> &lt; 0.03). This result is consistent with that of Bowen et al. [</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="19564" xml_f="19565" txt_i="14105" txt_f="14106">6</offsets></xref><offsets xml_i="19572" xml_f="19816" txt_i="14106" txt_f="14350">] who reported that levels of L in the serum were higher for subjects consuming the esterified form of L compared with those consuming free L. We also found that the change in MPOD bore a negative relationship with the presupplementation MPOD (</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="19848" xml_f="19856" txt_i="14350" txt_f="14358">Figure 2</offsets></xref><offsets xml_i="19863" xml_f="20203" txt_i="14358" txt_f="14698">), albeit significant only for Group 1. However, the difference in the MPOD increases for Groups 1 and 2 could not be attributed to this finding since the average presupplementation MPODs were 0.499 and 0.477, respectively. We also considered the possible influence of statins since use of this drug may reduce L and Z levels in the serum [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="20235" xml_f="20237" txt_i="14698" txt_f="14700">13</offsets></xref><offsets xml_i="20244" xml_f="20438" txt_i="14700" txt_f="14894">] and, by extension, in the retina. However, because there were more statin users in Group 1 than in Group 2, we can rule out statin use as a contributor to the larger MPOD increase for Group 1.</offsets></p><p><offsets xml_i="20445" xml_f="20718" txt_i="14895" txt_f="15168">There have been a number of other studies that examined the effect of lutein supplementation on MPOD. Direct comparisons are often difficult because of different doses, different supplementation periods, or different MPOD measurement parameters. For example, Nolan et al. [</offsets><xref rid="B14" ref-type="bibr"><offsets xml_i="20750" xml_f="20752" txt_i="15168" txt_f="15170">14</offsets></xref><offsets xml_i="20759" xml_f="21181" txt_i="15170" txt_f="15592">] supplemented their subjects with 20 mg per day of a mixture of unesterified L, Z, and MZ (10 : 10 : 2). After 6 months, MPOD measured at 0.23° eccentricity increased by ∼0.06. Although this is very similar to the increase observed in the present study for subjects taking the esterified 10 : 10 : 2 mixture, MPOD measured with a 1.5° stimulus will always be significantly lower than that measured at 0.23° eccentricity [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="21212" xml_f="21213" txt_i="15592" txt_f="15593">4</offsets></xref><offsets xml_i="21220" xml_f="21253" txt_i="15593" txt_f="15626">]. In a study by Schalch et al. [</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="21285" xml_f="21287" txt_i="15626" txt_f="15628">15</offsets></xref><offsets xml_i="21294" xml_f="21667" txt_i="15628" txt_f="16001">], one group of subjects received ∼20 mg/day of a mixture of L (∼10 mg) and Z (∼10 mg) for 6 months. MPOD measured by HFP with a 1° stimulus resulted in an average increase in MPOD of ∼15%. Again, this is similar to our own results which yielded ∼16% and ∼10% increases for Groups 1 and 2, respectively. Smaller increases in normal subjects were reported by Aleman et al. [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="21698" xml_f="21699" txt_i="16001" txt_f="16002">4</offsets></xref><offsets xml_i="21706" xml_f="21948" txt_i="16002" txt_f="16244">], whose subjects were supplemented with 20 mg/day of L for 6 months. The average increase was only 0.01 when measured by HFP with a 1° stimulus. However, the average increase was 0.07 for patients with retinitis pigmentosa or Usher syndrome.</offsets></p><p><offsets xml_i="21955" xml_f="21967" txt_i="16245" txt_f="16257">As shown in </offsets><xref ref-type="table" rid="tab4"><offsets xml_i="22001" xml_f="22008" txt_i="16257" txt_f="16264">Table 4</offsets></xref><offsets xml_i="22015" xml_f="22330" txt_i="16264" txt_f="16579">, age was not a significant factor in determining the change in MPOD resulting from supplementation. This was true for Groups 1 and 2 individually or in combination. We also examined the data to see whether the larger change in MPOD for Group 1 subjects compared with Group 2 subjects was age-dependent. As seen in </offsets><xref ref-type="table" rid="tab5"><offsets xml_i="22364" xml_f="22371" txt_i="16579" txt_f="16586">Table 5</offsets></xref><offsets xml_i="22378" xml_f="22735" txt_i="16586" txt_f="16943">, both the young and old subjects in Group 1 had a larger change in MPOD than their counterparts in Group 2. However, the difference was largely due to the older subjects whose increase in MPOD was 144% higher for Group 1 than Group 2 subjects compared with 36% for the younger subjects. The difference for the older subjects was statistically significant (</offsets><italic><offsets xml_i="22743" xml_f="22744" txt_i="16943" txt_f="16944">p</offsets></italic><offsets xml_i="22753" xml_f="22766" txt_i="16944" txt_f="16954"> &lt; 0.05). </offsets><xref ref-type="table" rid="tab4"><offsets xml_i="22800" xml_f="22807" txt_i="16954" txt_f="16961">Table 4</offsets></xref><offsets xml_i="22814" xml_f="23060" txt_i="16961" txt_f="17207"> also contradicts a claim, popular among some in the supplement industry, that MPOD declines with age. Although not statistically significant, the average presupplementation MPOD for the combined groups was actually higher for the older subjects.</offsets></p><p><offsets xml_i="23067" xml_f="23279" txt_i="17208" txt_f="17420">Prior to supplementation, the male subjects had, on average, a 17% higher MPOD than the female subjects, though the difference was not significant. Similar gender-based differences have been reported previously [</offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="23311" xml_f="23313" txt_i="17420" txt_f="17422">16</offsets></xref><offsets xml_i="23320" xml_f="23586" txt_i="17422" txt_f="17688">]. A possible reason could be that the diet of the male subjects resulted, on average, in a higher intake of xanthophylls than for the female subjects, but this was not assessed in this study. However, the increase in MPOD was almost identical for males and females.</offsets></p><p><offsets xml_i="23593" xml_f="24329" txt_i="17689" txt_f="18425">With the use of statin drugs being commonplace among older persons, statin use was not included as an exclusion criterion. Nor did the study design include a comparison of MPOD responses between statin users and nonusers. Nevertheless, we noted that prior to supplementation, the statin users had, on average, a 22% higher MPOD than the nonusers. On the other hand, the change in MPOD was 29% lower for the statin users, but neither difference was statistically significant, probably owing to the small number (9) of statin users. Because these findings appear to contradict each other, we are unable to present evidence to either refute or support the earlier finding that statin use was associated with lower serum levels of L and Z [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="24361" xml_f="24363" txt_i="18425" txt_f="18427">13</offsets></xref><offsets xml_i="24370" xml_f="24422" txt_i="18427" txt_f="18479">]. Our results could also simply be a reflection of </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="24454" xml_f="24462" txt_i="18479" txt_f="18487">Figure 2</offsets></xref><offsets xml_i="24469" xml_f="24559" txt_i="18487" txt_f="18577">, that is, subjects whose baseline MPOD is high generally have a smaller increase in MPOD.</offsets></p><p><offsets xml_i="24566" xml_f="24790" txt_i="18578" txt_f="18802">The limitations of this study include the lack of a placebo group. However, our past experience has led us to conclude that MPOD changes over a 6 month period are insignificant when subjects are assigned to a placebo group [</offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="24822" xml_f="24824" txt_i="18802" txt_f="18804">17</offsets></xref><offsets xml_i="24831" xml_f="24833" txt_i="18804" txt_f="18806">, </offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="24865" xml_f="24867" txt_i="18806" txt_f="18808">18</offsets></xref><offsets xml_i="24874" xml_f="25943" txt_i="18808" txt_f="19877">]. Also, we did not include an assessment of the subjects' dietary intake of xanthophylls which we would expect to influence their presupplementation MPOD. On the other hand, the supplements provided an approximately 10-fold increase in xanthophyll intake over the average dietary intake, so the subjects' diets would not be expected to influence changes in MPOD in any significant way. Lack of serum analysis of carotenoids in this report might also be considered a limitation; however, the target tissue for this study was the neural retina where the beneficial effects of the macular carotenoids are believed to occur. Finally, we did not use a mixture of unesterified L, Z, and MZ as our control. Therefore, it might be argued that the larger increase in MPOD observed for the diacetate group was a result of the inclusion of the zeaxanthin stereoisomers in the supplement rather than the esterification. We would argue against this possibility based on past observations, including our own, that neither Z nor MZ appears to produce as large a change in MPOD as L [</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="25975" xml_f="25977" txt_i="19877" txt_f="19879">15</offsets></xref><offsets xml_i="25984" xml_f="25986" txt_i="19879" txt_f="19881">, </offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="26018" xml_f="26020" txt_i="19881" txt_f="19883">18</offsets></xref><offsets xml_i="26027" xml_f="26029" txt_i="19883" txt_f="19885">, </offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="26061" xml_f="26063" txt_i="19885" txt_f="19887">19</offsets></xref><offsets xml_i="26070" xml_f="26276" txt_i="19887" txt_f="20093">]. Nonetheless, we acknowledge the report by Loughman et al. who found that supplementation with all three macular carotenoids produced significant increases in MPOD whereas supplementation with L did not [</offsets><xref rid="B20" ref-type="bibr"><offsets xml_i="26308" xml_f="26310" txt_i="20093" txt_f="20095">20</offsets></xref><offsets xml_i="26317" xml_f="26319" txt_i="20095" txt_f="20097">].</offsets></p></sec><sec id="sec5"><title><offsets xml_i="26351" xml_f="26365" txt_i="20099" txt_f="20113">5. Conclusions</offsets></title><p><offsets xml_i="26376" xml_f="26689" txt_i="20114" txt_f="20427">In conclusion, we have found that a combination of macular carotenoids in diacetate form was more effective at raising MPOD than unesterified L, especially in older subjects. This suggests that these particular esters may be more readily absorbed, that is, more bioavailable, than their unesterified counterparts.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Industrial Orgánica S.A. de C.V. for financial support for this study and for providing the supplements. Additional support was provided by Beneseed Co., Ltd.</p></ack><sec><title>Conflicts of Interest</title><p>The authors declare that there are no conflicts of interest regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bone</surname><given-names>R. A.</given-names></name><name><surname>Landrum</surname><given-names>J. T.</given-names></name></person-group><article-title>Comments on enrichment of macular pigment enhances contrast sensitivity in subjects free of retinal disease: CREST-report 1</article-title><source><italic>Investigative Ophthalmology and Visual Science</italic></source><year>2016</year><volume>57</volume><issue>13</issue><fpage>p. 5415</fpage><pub-id pub-id-type="doi">10.1167/iovs.16-20295</pub-id><pub-id pub-id-type="other">2-s2.0-84991677417</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krinsky</surname><given-names>N. I.</given-names></name><name><surname>Landrum</surname><given-names>J. T.</given-names></name><name><surname>Bone</surname><given-names>R. A.</given-names></name></person-group><article-title>Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye</article-title><source><italic>Annual Review of Nutrition</italic></source><year>2003</year><volume>23</volume><issue>1</issue><fpage>171</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1146/annurev.nutr.23.011702.073307</pub-id><pub-id pub-id-type="other">2-s2.0-0042866149</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro Lima</surname><given-names>V.</given-names></name><name><surname>Rosen</surname><given-names>R. B.</given-names></name><name><surname>Maia</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Macular pigment optical density measured by dual-wavelength autofluorescence imaging in diabetic and nondiabetic patients: a comparative study</article-title><source><italic>Investigative Ophthalmology and Visual Science</italic></source><year>2010</year><volume>51</volume><issue>11</issue><fpage>5840</fpage><lpage>5845</lpage><pub-id pub-id-type="doi">10.1167/iovs.09-4695</pub-id><pub-id pub-id-type="other">2-s2.0-79956047782</pub-id><pub-id pub-id-type="pmid">20505210</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleman</surname><given-names>T. S.</given-names></name><name><surname>Duncan</surname><given-names>J. L.</given-names></name><name><surname>Bieber</surname><given-names>M. L.</given-names></name><etal></etal></person-group><article-title>Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome</article-title><source><italic>Investigative Ophthalmology and Visual Science</italic></source><year>2001</year><volume>42</volume><issue>8</issue><fpage>1873</fpage><lpage>1881</lpage><pub-id pub-id-type="pmid">11431456</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bone</surname><given-names>R. A.</given-names></name><name><surname>Landrum</surname><given-names>J. T.</given-names></name></person-group><article-title>Dose-dependent response of serum lutein and macular pigment optical density to supplementation with lutein esters</article-title><source><italic>Archives of Biochemistry and Biophysics</italic></source><year>2010</year><volume>504</volume><issue>1</issue><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2010.06.019</pub-id><pub-id pub-id-type="other">2-s2.0-77957895626</pub-id><pub-id pub-id-type="pmid">20599660</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>P. E.</given-names></name><name><surname>Herbst-Espinosa</surname><given-names>S. M.</given-names></name><name><surname>Erum</surname><given-names>A.</given-names></name><name><surname>Stacewicz-Sapuntzakis</surname><given-names>M.</given-names></name></person-group><article-title>Esterification does not impair lutein bioavailability in humans</article-title><source><italic>Journal of Nutrition</italic></source><year>2002</year><volume>132</volume><issue>12</issue><fpage>3668</fpage><lpage>3673</lpage><pub-id pub-id-type="doi">10.1093/jn/132.12.3668</pub-id><pub-id pub-id-type="pmid">12468605</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surendranath</surname><given-names>R.</given-names></name><name><surname>Ganga</surname><given-names>M.</given-names></name><name><surname>Jawaharlal</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Extraction and quantification of marigold lutein using different solvent systems</article-title><source><italic>International Journal of Pharmaceutical Sciences Review and Research</italic></source><year>2016</year><volume>37</volume><issue>2</issue><fpage>187</fpage><lpage>191</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>H. Y.</given-names></name><name><surname>Rasmussen</surname><given-names>H. M.</given-names></name><name><surname>Johnson</surname><given-names>E. J.</given-names></name></person-group><article-title>Lutein bioavailability is higher from lutein-enriched eggs than from supplements and spinach in men</article-title><source><italic>Journal of Nutrition</italic></source><year>2004</year><volume>134</volume><issue>8</issue><fpage>1887</fpage><lpage>1893</lpage><pub-id pub-id-type="doi">10.1093/jn/134.8.1887</pub-id><pub-id pub-id-type="pmid">15284371</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landrum</surname><given-names>J. T.</given-names></name><name><surname>Bone</surname><given-names>R. A.</given-names></name><name><surname>Joa</surname><given-names>H.</given-names></name><name><surname>Kilburn</surname><given-names>M. D.</given-names></name><name><surname>Moore</surname><given-names>L. L.</given-names></name><name><surname>Sprague</surname><given-names>K. E.</given-names></name></person-group><article-title>A one year study of the macular pigment: the effect of 140 days of a lutein supplement</article-title><source><italic>Experimental Eye Research</italic></source><year>1997</year><volume>65</volume><issue>1</issue><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1006/exer.1997.0309</pub-id><pub-id pub-id-type="other">2-s2.0-0030752005</pub-id><pub-id pub-id-type="pmid">9237865</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeimer</surname><given-names>M.</given-names></name><name><surname>Dietzel</surname><given-names>M.</given-names></name><name><surname>Hense</surname><given-names>H. W.</given-names></name><name><surname>Heimes</surname><given-names>B.</given-names></name><name><surname>Austermann</surname><given-names>U.</given-names></name><name><surname>Pauleikhoff</surname><given-names>D.</given-names></name></person-group><article-title>Profiles of macular pigment optical density and their changes following supplemental lutein and zeaxanthin: new results from the LUNA study</article-title><source><italic>Investigative Ophthalmology and Visual Science</italic></source><year>2012</year><volume>53</volume><issue>8</issue><fpage>4852</fpage><lpage>4859</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-9713</pub-id><pub-id pub-id-type="other">2-s2.0-84867312501</pub-id><pub-id pub-id-type="pmid">22743321</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bone</surname><given-names>R. A.</given-names></name><name><surname>Mukherjee</surname><given-names>A.</given-names></name></person-group><article-title>Innovative Troxler-free measurement of macular pigment and lens density with correction of the former for the aging lens</article-title><source><italic>Journal of Biomedical Optics</italic></source><year>2013</year><volume>18</volume><issue>10</issue><fpage>107003-1</fpage><lpage>107003-8</lpage><pub-id pub-id-type="doi">10.1117/1.jbo.18.10.107003</pub-id><pub-id pub-id-type="other">2-s2.0-84886779418</pub-id><pub-id pub-id-type="pmid">24114020</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olive</surname><given-names>K. A.</given-names></name><name><surname>Agashe</surname><given-names>K.</given-names></name><name><surname>Amsler</surname><given-names>C.</given-names></name><etal></etal></person-group><article-title>Particle data group—Introduction</article-title><source><italic>Chinese Physics C</italic></source><year>2014</year><volume>38</volume><issue>9</issue><fpage>11</fpage><lpage>17</lpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rydén</surname><given-names>M.</given-names></name><name><surname>Leanderson</surname><given-names>P.</given-names></name><name><surname>Kastbom</surname><given-names>K. O.</given-names></name><name><surname>Jonasson</surname><given-names>L.</given-names></name></person-group><article-title>Effects of simvastatin on carotenoid status in plasma</article-title><source><italic>Nutrition, Metabolism and Cardiovascular Diseases</italic></source><year>2012</year><volume>22</volume><issue>1</issue><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2010.04.009</pub-id><pub-id pub-id-type="other">2-s2.0-83855165827</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolan</surname><given-names>J. M.</given-names></name><name><surname>Power</surname><given-names>R.</given-names></name><name><surname>Stringham</surname><given-names>J.</given-names></name><etal></etal></person-group><article-title>Enrichment of macular pigment enhances contrast sensitivity in subjects free of retinal disease: central retinal enrichment supplementation trials—report 1</article-title><source><italic>Investigative Ophthalmology and Visual Science</italic></source><year>2016</year><volume>57</volume><issue>7</issue><fpage>3429</fpage><lpage>3439</lpage><pub-id pub-id-type="doi">10.1167/iovs.16-19520</pub-id><pub-id pub-id-type="other">2-s2.0-84994571112</pub-id><pub-id pub-id-type="pmid">27367585</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schalch</surname><given-names>W.</given-names></name><name><surname>Cohn</surname><given-names>W.</given-names></name><name><surname>Barker</surname><given-names>F. M.</given-names></name><etal></etal></person-group><article-title>Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin—the LUXEA (LUtein Xanthophyll Eye Accumulation) study</article-title><source><italic>Archives of Biochemistry and Biophysics</italic></source><year>2007</year><volume>458</volume><issue>2</issue><fpage>128</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2006.09.032</pub-id><pub-id pub-id-type="other">2-s2.0-33846893634</pub-id><pub-id pub-id-type="pmid">17084803</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname><given-names>B. R.</given-names></name><name><surname>Curran-Celentano</surname><given-names>J.</given-names></name><name><surname>Judd</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Sex differences in macular pigment optical density: relation to plasma carotenoid concentrations and dietary patterns</article-title><source><italic>Vision Research</italic></source><year>1996</year><volume>36</volume><issue>13</issue><fpage>2001</fpage><lpage>2012</lpage><pub-id pub-id-type="doi">10.1016/0042-6989(95)00290-1</pub-id><pub-id pub-id-type="other">2-s2.0-0029955177</pub-id><pub-id pub-id-type="pmid">8759440</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landrum</surname><given-names>J.</given-names></name><name><surname>Bone</surname><given-names>R.</given-names></name><name><surname>Mendez</surname><given-names>V.</given-names></name><name><surname>Valenciaga</surname><given-names>A.</given-names></name><name><surname>Babino</surname><given-names>D.</given-names></name></person-group><article-title>Comparison of dietary supplementation with lutein diacetate and lutein: a pilot study of the effects on serum and macular pigment</article-title><source><italic>Acta Biochimica Polonica</italic></source><year>2012</year><volume>59</volume><issue>1</issue><fpage>167</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">22428144</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bone</surname><given-names>R. A.</given-names></name><name><surname>Landrum</surname><given-names>J. T.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Howard</surname><given-names>A. N.</given-names></name><name><surname>Alvarez-Calderon</surname><given-names>F.</given-names></name></person-group><article-title>Macular pigment response to a supplement containing meso-zeaxanthin, lutein and zeaxanthin</article-title><source><italic>Nutrition and Metabolism</italic></source><year>2007</year><volume>4</volume><issue>12</issue><fpage>p. 12</fpage><pub-id pub-id-type="doi">10.1186/1743-7075-4-12</pub-id><pub-id pub-id-type="other">2-s2.0-34248993217</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bone</surname><given-names>R. A.</given-names></name><name><surname>Landrum</surname><given-names>J. T.</given-names></name><name><surname>Guerra</surname><given-names>L. H.</given-names></name><name><surname>Ruiz</surname><given-names>C. A.</given-names></name></person-group><article-title>Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans</article-title><source><italic>Journal of Nutrition</italic></source><year>2003</year><volume>133</volume><issue>4</issue><fpage>992</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1093/jn/133.4.992</pub-id><pub-id pub-id-type="pmid">12672909</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loughman</surname><given-names>J.</given-names></name><name><surname>Nolan</surname><given-names>J. M.</given-names></name><name><surname>Howard</surname><given-names>A. N.</given-names></name><name><surname>Connolly</surname><given-names>E.</given-names></name><name><surname>Meagher</surname><given-names>K.</given-names></name><name><surname>Beatty</surname><given-names>S.</given-names></name></person-group><article-title>The impact of macular pigment augmentation on visual performance using different carotenoid formulations</article-title><source><italic>Investigative Ophthalmology and Visual Science</italic></source><year>2012</year><volume>53</volume><issue>12</issue><fpage>7871</fpage><lpage>7880</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-10690</pub-id><pub-id pub-id-type="other">2-s2.0-84872201091</pub-id><pub-id pub-id-type="pmid">23132800</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>MPOD changes for an individual subject. This was a Group 1 subject taking 20 mg per day (equivalent free carotenoids) of diacetate esters of lutein, zeaxanthin, and mesozeaxanthin in a 10 : 10 : 2 ratio.</p></caption><graphic xlink:href="JNME2018-4632081.001"></graphic></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Change in MPOD as a function of presupplementation MPOD for all 46 subjects (23 taking 20 mg per day (equivalent free carotenoids) of diacetate esters of lutein, zeaxanthin, and mesozeaxanthin in a 10 : 10 : 2 ratio and 23 taking lutein).</p></caption><graphic xlink:href="JNME2018-4632081.002"></graphic></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Subject demographics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Group</th><th align="center" rowspan="2" colspan="1">Number of subjects</th><th align="center" colspan="2" rowspan="1">Number in age groups</th><th align="center" rowspan="2" colspan="1">Male/female</th><th align="center" colspan="3" rowspan="1">Average age ± SD in age groups</th><th align="center" rowspan="2" colspan="1">Supplement</th></tr><tr><th align="center" rowspan="1" colspan="1">18–30</th><th align="center" rowspan="1" colspan="1">&gt;50</th><th align="center" rowspan="1" colspan="1">All</th><th align="center" rowspan="1" colspan="1">18–30</th><th align="center" rowspan="1" colspan="1">&gt;50</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">9/15</td><td align="center" rowspan="1" colspan="1">42.9 ± 22.1</td><td align="center" rowspan="1" colspan="1">22.0 ± 3.0</td><td align="center" rowspan="1" colspan="1">63.8 ± 8.1</td><td align="center" rowspan="1" colspan="1">Micro Mic (L : MZ : Z : = 10 : 10 : 2)</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">13/11</td><td align="center" rowspan="1" colspan="1">40.5 ± 18.9</td><td align="center" rowspan="1" colspan="1">22.9 ± 2.8</td><td align="center" rowspan="1" colspan="1">58.0 ± 8.3</td><td align="center" rowspan="1" colspan="1">Lutein (∼5% Z)</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Compliance.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Percent compliance ± SD</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Group 1</td><td align="center" rowspan="1" colspan="1">95.6 ± 6.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Group 2</td><td align="center" rowspan="1" colspan="1">95.9 ± 5.4</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>MPOD changes ± SD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Change in MPOD (AU)</th><th align="center" rowspan="1" colspan="1">% change in MPOD</th><th align="center" rowspan="1" colspan="1">Rate of change in MPOD (mAU/week)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Group 1</td><td align="center" rowspan="1" colspan="1">0.0666 ± 0.0481</td><td align="center" rowspan="1" colspan="1">16.2 ± 12.8</td><td align="center" rowspan="1" colspan="1">2.54 ± 2.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Group 2</td><td align="center" rowspan="1" colspan="1">0.0398 ± 0.0430</td><td align="center" rowspan="1" colspan="1">10.4 ± 12.1</td><td align="center" rowspan="1" colspan="1">1.71 ± 1.83</td></tr></tbody></table><table-wrap-foot><fn><p>AU = absorbance units; mAU = milliabsorbance units.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Effect of age on MPOD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">All groups, young</th><th align="center" rowspan="1" colspan="1">All groups, old</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Presupplementation MPOD</td><td align="center" rowspan="1" colspan="1">0.440 ± 0.192</td><td align="center" rowspan="1" colspan="1">0.501 ± 0.142</td><td align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">Change MPOD</td><td align="center" rowspan="1" colspan="1">0.0617 ± 0.0479</td><td align="center" rowspan="1" colspan="1">0.0489 ± 0.0454</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">% change MPOD</td><td align="center" rowspan="1" colspan="1">18.0 ± 16.9</td><td align="center" rowspan="1" colspan="1">11.1 ± 11.4</td><td align="center" rowspan="1" colspan="1">0.075</td></tr><tr><td align="left" rowspan="1" colspan="1">Rate MPOD (mAU/wk)</td><td align="center" rowspan="1" colspan="1">2.46 ± 2.11</td><td align="center" rowspan="1" colspan="1">1.79 ± 1.79</td><td align="center" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" colspan="4" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">Group 1, young</td><td align="center" rowspan="1" colspan="1">Group 1, old</td><td align="center" rowspan="1" colspan="1">
<italic>p</italic>
</td></tr><tr><td align="left" colspan="4" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Presupplementation MPOD</td><td align="center" rowspan="1" colspan="1">0.510 ± 0.154</td><td align="center" rowspan="1" colspan="1">0.488 ± 0.110</td><td align="center" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Change MPOD</td><td align="center" rowspan="1" colspan="1">0.0669 ± 0.0509</td><td align="center" rowspan="1" colspan="1">0.0723 ± 0.0447</td><td align="center" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" rowspan="1" colspan="1">% change MPOD</td><td align="center" rowspan="1" colspan="1">16.0 ± 15.2</td><td align="center" rowspan="1" colspan="1">16.4 ± 10.7</td><td align="center" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" rowspan="1" colspan="1">Rate MPOD (mAU/wk)</td><td align="center" rowspan="1" colspan="1">2.53 ± 2.44</td><td align="center" rowspan="1" colspan="1">2.56 ± 1.68</td><td align="center" rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" colspan="4" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">Group 2, young</td><td align="center" rowspan="1" colspan="1">Group 2, old</td><td align="center" rowspan="1" colspan="1">
<italic>p</italic>
</td></tr><tr><td align="left" colspan="4" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Presupplementation MPOD</td><td align="center" rowspan="1" colspan="1">0.466 ± 0.215</td><td align="center" rowspan="1" colspan="1">0.488 ± 0.169</td><td align="center" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Change MPOD</td><td align="center" rowspan="1" colspan="1">0.0491 ± 0.0454</td><td align="center" rowspan="1" colspan="1">0.0296 ± 0.0398</td><td align="center" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">% change MPOD</td><td align="center" rowspan="1" colspan="1">13.6 ± 12.5</td><td align="center" rowspan="1" colspan="1">7.0 ± 11.2</td><td align="center" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">Rate MPOD (mAU/wk)</td><td align="center" rowspan="1" colspan="1">2.09 ± 2.03</td><td align="center" rowspan="1" colspan="1">1.30 ± 1.58</td><td align="center" rowspan="1" colspan="1">0.31</td></tr></tbody></table></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Change in MPOD for young and old subjects in Groups 1 and 2.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"> </th><th align="center" colspan="2" rowspan="1">Change in MPOD ± SD</th></tr><tr><th align="center" rowspan="1" colspan="1">Young</th><th align="center" rowspan="1" colspan="1">Old</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Group 1</td><td align="center" rowspan="1" colspan="1">0.0669 ± 0.0509</td><td align="center" rowspan="1" colspan="1">0.0723 ± 0.0447</td></tr><tr><td align="left" rowspan="1" colspan="1">Group 2</td><td align="center" rowspan="1" colspan="1">0.0491 ± 0.0454</td><td align="center" rowspan="1" colspan="1">0.0296 ± 0.0398</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>p</italic>
</td><td align="center" rowspan="1" colspan="1">0.39</td><td align="center" rowspan="1" colspan="1">0.025<sup>∗</sup></td></tr></tbody></table></table-wrap><table-wrap id="tab6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Gender effects on MPOD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Female</th><th align="center" rowspan="1" colspan="1">Male</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Presupplementation MPOD</td><td align="center" rowspan="1" colspan="1">0.450 ± 0.154</td><td align="center" rowspan="1" colspan="1">0.528 ± 0.163</td><td align="center" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" rowspan="1" colspan="1">Change MPOD</td><td align="center" rowspan="1" colspan="1">0.0556 ± 0.0504</td><td align="center" rowspan="1" colspan="1">0.0538 ± 0.0440</td><td align="center" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" rowspan="1" colspan="1">% change MPOD</td><td align="center" rowspan="1" colspan="1">14.5 ± 14.5</td><td align="center" rowspan="1" colspan="1">12.0 ± 10.5</td><td align="center" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">Rate MPOD (mAU/wk)</td><td align="center" rowspan="1" colspan="1">2.00 ± 2.19</td><td align="center" rowspan="1" colspan="1">2.26 ± 1.71</td><td align="center" rowspan="1" colspan="1">0.66</td></tr></tbody></table></table-wrap><table-wrap id="tab7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Effect of statin use on MPOD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Nonstatin users</th><th align="center" rowspan="1" colspan="1">Statin users</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Presupplementation MPOD</td><td align="center" rowspan="1" colspan="1">0.476 ± 0.163</td><td align="center" rowspan="1" colspan="1">0.536 ± 0.157</td><td align="center" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Change MPOD</td><td align="center" rowspan="1" colspan="1">0.0580 ± 0.0470</td><td align="center" rowspan="1" colspan="1">0.0413 ± 0.0467</td><td align="center" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">% change MPOD</td><td align="center" rowspan="1" colspan="1">14.1 ± 12.9</td><td align="center" rowspan="1" colspan="1">10.0 ± 11.8</td><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Rate MPOD (mAU/wk)</td><td align="center" rowspan="1" colspan="1">2.23 ± 2.02</td><td align="center" rowspan="1" colspan="1">1.72 ± 1.71</td><td align="center" rowspan="1" colspan="1">0.45</td></tr></tbody></table></table-wrap></floats-group></article>